CANADA LIFE ASSURANCE Co Sells 32,328 Shares of Eli Lilly and Company (NYSE:LLY)

CANADA LIFE ASSURANCE Co lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 753,434 shares of the company's stock after selling 32,328 shares during the period. Eli Lilly and Company accounts for 1.0% of CANADA LIFE ASSURANCE Co's portfolio, making the stock its 13th largest holding. CANADA LIFE ASSURANCE Co owned about 0.08% of Eli Lilly and Company worth $581,799,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of LLY. Principal Financial Group Inc. boosted its stake in shares of Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after purchasing an additional 60,306 shares during the last quarter. M&T Bank Corp raised its position in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. M&T Bank Corp now owns 266,822 shares of the company's stock valued at $236,389,000 after acquiring an additional 1,867 shares during the last quarter. Invst LLC raised its position in shares of Eli Lilly and Company by 3.5% during the 3rd quarter. Invst LLC now owns 5,552 shares of the company's stock valued at $4,918,000 after acquiring an additional 189 shares during the last quarter. McIlrath & Eck LLC boosted its position in shares of Eli Lilly and Company by 3.4% in the 3rd quarter. McIlrath & Eck LLC now owns 481 shares of the company's stock worth $426,000 after purchasing an additional 16 shares during the last quarter. Finally, Virtu Financial LLC grew its stake in shares of Eli Lilly and Company by 111.7% during the third quarter. Virtu Financial LLC now owns 6,531 shares of the company's stock worth $5,786,000 after purchasing an additional 3,446 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on LLY shares. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research note on Thursday, January 16th. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a report on Friday, January 17th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, Morgan Stanley decreased their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. Two equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $1,012.00.

Eli Lilly and Company Stock Performance

LLY stock traded up $106.80 during trading hours on Friday, reaching $841.70. The stock had a trading volume of 10,843,294 shares, compared to its average volume of 3,427,703. The stock has a 50-day simple moving average of $829.09 and a 200 day simple moving average of $820.35. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The stock has a market capitalization of $798.08 billion, a PE ratio of 71.88, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.